Final Operational Milestone #6

The ACES study evaluated the safety and effectiveness of immune cell therapy targeting three viruses that often complicate bone marrow transplantation.   We treated 51 patients (47 after bone marrow transplantation, and 4 with congenital immunodeficiency pre-transplantation) for refractory viral infections, and achieved antiviral responses in 60% of subjects by 1 month after cell infusion.   Cell infusions were generally well tolerated, with adverse reactions potentially caused by the infusions in 4 patients.  Infusions restored antiviral immunity in 60% of patients tested by 1-3 months after infusions.